Design of Cytokine/antibody Fusion Proteins to Develop Novel Immunotherapeutics

Time: 4:40 pm
day: Conference Day One


  • Linking interleukin-2 (IL-2) to an anti-IL-2 antibody modulates cytokine behavior for selective and effective disease targeting
  • Cytokine pleiotropy allows for development of interventions against cancer, infection, and autoimmune diseases
  • Structural insights guide engineering of cytokine/antibody fusion proteins to optimize assembly, stability, and therapeutic activity